Los Angeles, December 8, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce that distinguished researcher Michael Shepard, PhD has joined Trethera’s Scientific Advisory Board. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards for his contributions to the development of innovative therapies including the prestigious Lasker-DeBakey Clinical Medical Research Award in 2019. Founded in 1945, the Lasker-DeBakey award is widely regarded as a top global biomedical research prize.
“We are honored to have Dr. Shepard join Trethera’s Scientific Advisory Board. Dr. Shepard is an internationally recognized industry pioneer who has helped develop breakthrough autoimmune and cancer therapies such as Herceptin,” said Dr. Kenneth Schultz, Chairman and CEO of Trethera. “Dr. Shepard joins us at an exciting time as we continue to develop TRE-515, our first-in-class dCK inhibitor for multiple indications. He has deep experience expanding cancer drugs to treat inflammatory and autoimmune diseases”.
Dr. Shepard, currently the President and CEO of Enosi Life Sciences, is best known for his pioneering work at Genetech where he led the team that discovered the antibody that attacks HER2-tumor cells that later became known as Herceptin. Herceptin is a life-saving therapy for women with breast cancer, reducing the risk of recurrence while extending survival times. While still at Genetech, Dr. Shepard also collaborated with fellow renowned researcher Sir Marc Feldmann, to develop Remicade, a TNF inhibitor now used to treat multiple autoimmune diseases. Dr. Shepard is also a recipient of the Warren Alpert Foundation Prize from the Harvard Medical School, a significant award given to scientists whose achievements have led to the prevention, cure or treatment of human diseases.
“At this juncture in my career I continually have the opportunity to be selective and work on therapies that show promise. I am very excited to be chosen to work with the Trethera team,” said Dr. Shepard. “I have found that Trethera’s small molecule inhibitor of deoxycytidine kinase, TRE-515, is an encouraging development with the potential to treat autoimmune diseases such as multiple sclerosis and certain forms of cancer. I look forward to lending expertise and advising them on their path toward clinical trials.”
Trethera is a preclinical stage privately held biopharmaceutical company dedicated to pioneering the development of novel treatments for autoimmune diseases and cancers. Founded by prominent UCLA scientists, Trethera is led by experienced management and board members. Trethera’s innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally taken capsule. TRE-515 is a first-in-class preclinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors. It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth. Certain autoimmune diseases might respond to TRE-515 treatment. Trethera is developing TRE-515 for use as a monotherapy or in combination, to precisely target a metabolic vulnerability of cancer cells or autoimmune diseases that will transform outcomes for patients.
Note on Forward-Looking Statements
All statements other than statements of historical facts included in this press release that address activities, events or developments that Trethera believes or anticipates will or may occur in the future are “forward-looking statements” which may often, but not always, be identified by the use of such words as “may”, “might”, “will”, “will likely result”, “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek,” “continue”, “target” or the negative of such terms or other similar expressions. Although Trethera has a reasonable basis for the forward-looking statements contained herein, Trethera cautions that such statements are based on current expectations about future events and are subject to risks, uncertainties and factors relating to medical and scientific research, all of which are difficult to predict and many of which are beyond Trethera’s control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release. These potential risks and uncertainties include, without limitation: the extent to which development of any novel cancer therapies or therapies for autoimmune diseases succeeds; whether Trethera would obtain the necessary regulatory approvals to commence human trials or commercialize TRE-515 or any novel therapies resulting from such research; Trethera successfully implementing its growth strategy, including that relating to its disease therapies; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; and risks and uncertainties applicable to the business of Trethera. The statements in this press release speak only as of the date hereof and Trethera does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.